Bearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimates [Yahoo! Finance]
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Assembly Biosciences, Inc. (NASDAQ: ASMB) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
Assembly Biosciences, Inc. (NASDAQ: ASMB) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $35.00 price target on the stock, up previously from $2.00.